| pubmed-article:1712246 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1712246 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:1712246 | lifeskim:mentions | umls-concept:C0034693 | lld:lifeskim |
| pubmed-article:1712246 | lifeskim:mentions | umls-concept:C0079459 | lld:lifeskim |
| pubmed-article:1712246 | lifeskim:mentions | umls-concept:C0031327 | lld:lifeskim |
| pubmed-article:1712246 | lifeskim:mentions | umls-concept:C0032483 | lld:lifeskim |
| pubmed-article:1712246 | lifeskim:mentions | umls-concept:C0522529 | lld:lifeskim |
| pubmed-article:1712246 | pubmed:issue | 14 | lld:pubmed |
| pubmed-article:1712246 | pubmed:dateCreated | 1991-8-12 | lld:pubmed |
| pubmed-article:1712246 | pubmed:abstractText | The pharmacokinetics of recombinant human granulocyte colony-stimulating factor conjugated to polyethylene glycol (PEG-rhG-CSF) and rhG-CSF were studied in male Sprague-Dawley rats. The serum concentration after i.v. administration at a dose of 100 micrograms protein/kg was investigated by a bioassay. The serum rhG-CSF concentration decreased steadily after injection with a terminal half-life of 1.79 h. The PEG-rhG-CSF concentration after injection decreased much more slowly with a half-life of 7.05 h. The slower disappearance of PEG-rhG-CSF resulted in a greater area under the concentration-time curve. The neutrophil count after 100 micrograms of protein/kg of rhG-CSF administration reached a peak 12 h after injection and returned to the control level 48 h after injection. The neutrophil count after 100 micrograms of protein/kg of PEG-rhG-CSF administration was identical to that of rhG-CSF after 12 h but the highest level was maintained for 24 to 72 h after injection and returned to the control level after 168 h. These data indicated that PEG-rhG-CSF administration exerted a sustained biological effect on peripheral blood neutrophils. It is expected that PEG-rhG-CSF may contribute greatly to human G-CSF treatment because it has a prolonged neutrophil-proliferating activity enabling fewer administrations. | lld:pubmed |
| pubmed-article:1712246 | pubmed:language | eng | lld:pubmed |
| pubmed-article:1712246 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1712246 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:1712246 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1712246 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1712246 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1712246 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1712246 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:1712246 | pubmed:issn | 0008-5472 | lld:pubmed |
| pubmed-article:1712246 | pubmed:author | pubmed-author:IshikawaMM | lld:pubmed |
| pubmed-article:1712246 | pubmed:author | pubmed-author:TanakaHH | lld:pubmed |
| pubmed-article:1712246 | pubmed:author | pubmed-author:AsanoKK | lld:pubmed |
| pubmed-article:1712246 | pubmed:author | pubmed-author:MatsukiSS | lld:pubmed |
| pubmed-article:1712246 | pubmed:author | pubmed-author:Satake-Ishika... | lld:pubmed |
| pubmed-article:1712246 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1712246 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:1712246 | pubmed:volume | 51 | lld:pubmed |
| pubmed-article:1712246 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1712246 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:1712246 | pubmed:pagination | 3710-4 | lld:pubmed |
| pubmed-article:1712246 | pubmed:dateRevised | 2003-11-14 | lld:pubmed |
| pubmed-article:1712246 | pubmed:meshHeading | pubmed-meshheading:1712246-... | lld:pubmed |
| pubmed-article:1712246 | pubmed:meshHeading | pubmed-meshheading:1712246-... | lld:pubmed |
| pubmed-article:1712246 | pubmed:meshHeading | pubmed-meshheading:1712246-... | lld:pubmed |
| pubmed-article:1712246 | pubmed:meshHeading | pubmed-meshheading:1712246-... | lld:pubmed |
| pubmed-article:1712246 | pubmed:meshHeading | pubmed-meshheading:1712246-... | lld:pubmed |
| pubmed-article:1712246 | pubmed:meshHeading | pubmed-meshheading:1712246-... | lld:pubmed |
| pubmed-article:1712246 | pubmed:meshHeading | pubmed-meshheading:1712246-... | lld:pubmed |
| pubmed-article:1712246 | pubmed:meshHeading | pubmed-meshheading:1712246-... | lld:pubmed |
| pubmed-article:1712246 | pubmed:meshHeading | pubmed-meshheading:1712246-... | lld:pubmed |
| pubmed-article:1712246 | pubmed:meshHeading | pubmed-meshheading:1712246-... | lld:pubmed |
| pubmed-article:1712246 | pubmed:meshHeading | pubmed-meshheading:1712246-... | lld:pubmed |
| pubmed-article:1712246 | pubmed:year | 1991 | lld:pubmed |
| pubmed-article:1712246 | pubmed:articleTitle | Pharmacokinetics of recombinant human granulocyte colony-stimulating factor conjugated to polyethylene glycol in rats. | lld:pubmed |
| pubmed-article:1712246 | pubmed:affiliation | Kirin Brewery Co., Ltd., Pharmaceutical Development Laboratory, Gunma, Japan. | lld:pubmed |
| pubmed-article:1712246 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1712246 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1712246 | lld:pubmed |
